Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.74%.

  • BridgeBio Pharma's Return on Capital Employed rose 1800.0% to 0.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74%, marking a year-over-year increase of 1800.0%. This contributed to the annual value of 1.03% for FY2024, which is 3500.0% up from last year.
  • Per BridgeBio Pharma's latest filing, its Return on Capital Employed stood at 0.74% for Q3 2025, which was up 1800.0% from 0.82% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Return on Capital Employed ranged from a high of 0.53% in Q2 2021 and a low of 1.33% during Q4 2023
  • In the last 5 years, BridgeBio Pharma's Return on Capital Employed had a median value of 0.82% in 2022 and averaged 0.86%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -4100bps in 2023, then skyrocketed by 4300bps in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Return on Capital Employed stood at 0.76% in 2021, then decreased by -22bps to 0.92% in 2022, then crashed by -44bps to 1.33% in 2023, then skyrocketed by 30bps to 0.93% in 2024, then rose by 20bps to 0.74% in 2025.
  • Its last three reported values are 0.74% in Q3 2025, 0.82% for Q2 2025, and 0.93% during Q1 2025.